|
Nov 7
|
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
|
|
Nov 6
|
High Growth Tech Stocks In The United States To Watch
|
|
Nov 5
|
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
|
|
Nov 5
|
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology
|
|
Nov 5
|
Ascendis Pharma and Novo Nordisk Join Forces
|
|
Nov 5
|
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform
|
|
Nov 4
|
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug
|
|
Nov 4
|
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug
|
|
Nov 4
|
Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases
|
|
Nov 4
|
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
|
|
Jul 24
|
Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year
|